News | June 03, 2011

Long Lesion Study Demonstrates Supera Stent Efficacy in SFA and Popliteal Arteries

June 3, 2011 - IDEV Technologies announced that data from a long lesion study of 182 patients with significantly diseased superficial femoral arteries and popliteal arteries showed high patency rates and no stent fractures after treatment with the Supera Veritas Peripheral Vascular Stent System. The data were presented at the Vaatdagen 2011 (Vascular Days) Conference based on analysis by Andre Molenaar, M.D., and Peter Haarbrink, M.D., interventional radiologists at Canisius-Wilhelmina Ziekenhuis (CWZ) hospital, a leading teaching and high volume medical center in Nijmegen, The Netherlands.

The patients were treated and followed over a two-year period, and represented an extremely challenging patient cohort with highly calcified and long lesions in the superficial femoral artery (SFA) which at times encompassed the proximal popliteal artery and/or popliteal artery alone. The results were achieved in vessels with significant disease and atypical extremely long lesion lengths with no Plavix used.

The SFA plus proximal popliteal treated artery cohort consisted of 159 patients, with an average lesion length of 240 mm, 40 percent Tasc D classification, and 57 percent total occlusions with an average of nearly two stents per patient. A high patency rate of 74 percent was achieved at 12 months as measured by duplex ultrasound (DU). A group of 23 patients were treated with a Supera stent in the popliteal artery, with an average stent length of 142 mm and a patency rate of 83 percent at 12 months, again measured by DU. A subgroup analysis by X-ray at 24 months showed no stent fractures. These data compare favorably to standard nitinol stent performance in patients with significantly shorter lesions.

"These are outstanding and noteworthy results which demonstrate that Supera is a market-changing technology when used appropriately," stated Molenaar. "The average stent length deployed was 240 mm, ranging from 40 to 550 mm. Compared with other stent trials, and even the Leipzig Supera registry, these are much longer lesions with significant disease," added Haarbrink.

Molenaar added that no concomitant treatment occurred with antiplatelet medication. "Patients received aspirin post procedure but none of these patients received Plavix following their stent procedures. We can assume the results would have had an even more dramatic improvement from baseline had we supplemented our procedure with this treatment. It is also clear to us that we utilize Supera for the most challenging cases, constantly testing the device and still receive exceptional results. We look forward to continuing our analysis of Supera.

For more information:

Related Content

Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init